Pharmaceutical regulatory medical writing for document submissions to Western health regulatory agencies has been undertaken in India for almost 10 years. From humble beginnings in a couple of non-Indian pharmaceutical multinational giants – Novartis and Sanofi-Aventis (as it was) – this activity has now expanded into multiple companies and almost a dozen information technology firms and contract research organisations. The biggest advantage is the cost, although this often comes at a ‘price’, in terms of document quality. However, medical writing in India may be turning a corner for the good as a result of the rapidly increasing body of experience in the field.
Editor-in-Chief:
Co-Editor:
Managing Editor
Associate Editors:
Section Editors:
Ad-hoc Editors:
Editor Emeritus: